SCHEMBL260245

SCHEMBL260245

O=C1Cc2c(ccc(CN3CCOC3=O)c2F)N1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.36
DRD4 P21917 3/20 0.36
DRD3 P35462 3/20 0.36
ALDH1A1 P00352 3/20 0.33
GRM2 Q14416 2/20 0.33
GRIN1 Q05586 2/20 0.33
GRIN2B Q13224 2/20 0.33
PER2 O15055 1/20 0.33
CRY2 Q49AN0 1/20 0.33
NAAA Q02083 1/20 0.33
POLB P06746 2/20 0.32
KDM4E B2RXH2 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
CYP1A2 P05177 1/20 0.32
MAPT P10636 1/20 0.32
KCNH2 Q12809 2/20 0.31
NR1I2 O75469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260288 0.75 HTR1A (0.39) DRD2ALDH1A1GRIN1GRIN2BPER2
SCHEMBL12064441 0.73 DRD2 (0.44) DRD2DRD4DRD3KDM4ECYP3A4
SCHEMBL259907 0.73 GRM2 (0.33) ALDH1A1GRM2GRIN1GRIN2BPER2
SCHEMBL259627 0.72 MAOB (0.44) DRD2GRM2KCNH2NR1I2HTR1A
SCHEMBL31167079 0.70 ALDH1A1 (0.42) ALDH1A1GRM2GRIN1GRIN2BPER2
SCHEMBL19208571 0.69 P2RX7 (0.42) ALDH1A1GRM2CYP3A4CYP2D6CYP2C19
SCHEMBL29781764 0.69 P2RX7 (0.42) ALDH1A1GRM2CYP3A4CYP2D6CYP2C19
SCHEMBL31166814 0.69 CYP11B1 (0.45) ALDH1A1GRM2GRIN1GRIN2BPER2
SCHEMBL20695806 0.68 KDM4E (0.44) ALDH1A1GRM2NAAAPOLBKDM4E
SCHEMBL1951084 0.67 GRM2 (0.46) GRM2GRIN1GRIN2BOPRM1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541412-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-09-24 US disclosed
EP-2281822-B1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2013-01-16 EP disclosed
US-8133889-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-13 US disclosed
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-02-23 US disclosed
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-02-10 US disclosed
EP-2281822-A1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2011-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 DRD2 359/4885DRD4 251/4885DRD3 298/4885
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 DRD2 359/4885DRD4 251/4885DRD3 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.